SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000898432-19-001014
Filing Date
2019-07-24
Accepted
2019-07-24 16:08:25
Documents
2
Group Members
22NW FUND GP, LLC22NW FUND, LP22NW GP, INC.ARON R. ENGLISH

Document Format Files

Seq Description Document Type Size
1 sc_13d.htm SC 13D 172246
2 exhibit_99-1.htm EX-99.1 16107
  Complete submission text file 0000898432-19-001014.txt   190002
Mailing Address 611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO CA 94080 650-871-0761
CATALYST BIOSCIENCES, INC. (Subject) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-82442 | Film No.: 19971019
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1455 NW LEARY WAY, SUITE 400 SEATTLE WA 98107
Business Address 1455 NW LEARY WAY, SUITE 400 SEATTLE WA 98107 650-862-4295
22NW, LP (Filed by) CIK: 0001694297 (see all company filings)

IRS No.: 473089159 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D